High level of tumor marker CA19-9 returned to normal after cholecystectomy in calculous cholecystitis patients

References

• Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 1979;5(6):957–971.
   PubMedGoogle Scholar
• Li Y, Li D-J, Chen J, et al. Application of joint detection of AFP, CA19-9, CA125 and CEA in identification and diagnosis of cholangiocarcinoma. Asian Pac J Cancer Prev. 2015;16(8):3451–3455.
   PubMedGoogle Scholar
• Rao H, Wu H, Huang Q, et al. Clinical value of serum CEA, CA24-2 and CA19-9 in patients with colorectal cancer. Clin Lab. 2021;67(4). DOI:10.7754/Clin.Lab.2020.200828
   Web of Science ®Google Scholar
• Zhang J, Wang Y, Zhao T, et al. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer. World J Surg Oncol. 2020;18(1):31.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kim MH, Myung SJ, et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol. 1999;94(7):1941–1946.
   PubMed Web of Science ®Google Scholar
• Bind MK, Mishra RR, Kumar V, et al. Serum CA 19-9 and CA 125 as a diagnostic marker in carcinoma of gallbladder. Indian J Pathol Microbiol. 2021;64(1):65–68.
   PubMed Web of Science ®Google Scholar
• Ge L, Pan B, Song F, et al. Comparing the diagnostic accuracy of five common tumour biomarkers and CA19-9 for pancreatic cancer: a protocol for a network meta-analysis of diagnostic test accuracy. BMJ Open. 2017;7(12):e018175.
   PubMed Web of Science ®Google Scholar
• Jing R, Cui M, Ju S, et al. The changes and clinical significance of preoperative and postoperative serum CEA and CA19-9 in gastric cancer. Clin Lab. 2020;66(4). DOI:10.7754/Clin.Lab.2019.190732
   Web of Science ®Google Scholar
• Kambara Y, Miyake H, Nagai H, et al. CA19-9 is a significant prognostic marker of patients with stage III gastric cancer. Eur J Surg Oncol. 2020;46(10 Pt A):1918–1924.
   PubMed Web of Science ®Google Scholar
• Atkinson BF, Ernst CS, Herlyn M, et al. Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res. 1982;42(11):4820–4823.
   PubMed Web of Science ®Google Scholar
• Agrawal V, Goel A, Krishnani N, et al. p53, carcinoembryonic antigen and carbohydrate antigen 19.9 expression in gall bladder cancer, precursor epithelial lesions and xanthogranulomatous cholecystitis. J Postgrad Med. 2010;56(4):262–266.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Saitoh Y, Ohyanagi H, et al. Immunohistochemical staining of pancreatic cancer with CA19-9, KM01, unabsorbed CEA, and absorbed CEA. A comparison with normal pancreas and chronic pancreatitis. Arch Pathol Lab Med. 1990;114:195–200.
   PubMed Web of Science ®Google Scholar
• Eskelinen M, Haglund U. Developments in serologic detection of human pancreatic adenocarcinoma. Scand J Gastroenterol. 1999;34(9):833–844.
   PubMed Web of Science ®Google Scholar
• Ma S, Duan J, Li W, et al. Exploration of the value of MRCP combined with tumor marker CA19-9 in the diagnosis of pancreatic cancer. Artif Cells Nanomed Biotechnol. 2016;44(2):717–721.
   PubMed Web of Science ®Google Scholar
• Qin XL, Wang ZR, Shi JS, et al. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA. World J Gastroenterol. 2004;10(3):427–432.
   PubMed Web of Science ®Google Scholar
• Haglund C, Roberts PJ, Jalanko H, et al. Tumour markers CA 19-9 and CA 50 in digestive tract malignancies. Scand J Gastroenterol. 1992;27(3):169–174.
   PubMed Web of Science ®Google Scholar
• Kang JS, Hong SY, Han Y, et al. Limits of serum carcinoembryonic antigen and carbohydrate antigen 19-9 as the diagnosis of gallbladder cancer. Ann Surg Treat Res. 2021;101(5):266–273.
   PubMed Web of Science ®Google Scholar
• Benini L, Cavallini G, Zordan D, et al. A clinical evaluation of monoclonal (CA19-9, CA50, CA12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer. Pancreas. 1988;3:61–66.
   PubMed Web of Science ®Google Scholar
• Yoshikawa T, Nishida K, Tanigawa M, et al. Carbohydrate antigenic determinant (CA 19-9) and other tumor markers in gastrointestinal malignancies. Digestion. 1985;31(2-3):67–76.
   PubMed Web of Science ®Google Scholar
• Steinberg WM, Gelfand R, Anderson KK, et al. Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology. 1986;90(2):343–349.
   PubMed Web of Science ®Google Scholar
• Ong SL, Sachdeva A, Garcea G, et al. Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. Dig Dis Sci. 2008;53(12):3213–3217.
   PubMed Web of Science ®Google Scholar
• Moshref LH, Mandili RA, Almaghrabi M, et al. Elevation of CA 19-9 in mirizzi syndrome in the absence of malignancy: a case report. Am J Case Rep. 2021;22:e931819.
   PubMed Web of Science ®Google Scholar
• Haring MPD, de Cort BA, Nieuwenhuijs VB. [Elevated CA19-9 levels; not always cancer]. Ned Tijdschr Geneeskd. 2021;164:D4048.
   PubMedGoogle Scholar
• Akimoto S, Banshodani M, Nishihara M, et al. Acute cholecystitis with significantly elevated levels of serum carbohydrate antigen 19-9. Case Rep Gastroenterol. 2016;10(2):410–416.
   PubMedGoogle Scholar
• Şahin M, Cüre E, İşler M, et al. Elevated Ca 19-9 Levels in Patient With Cholecystitis. 2007.
   Google Scholar
• Yokoe M, Hata J, Takada T, et al. Tokyo guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos). J Hepatobiliary Pancreat Sci. 2018;25(1):41–54.
   PubMed Web of Science ®Google Scholar
• Domeyer PJ, Sergentanis TN, Zagouri F, et al. Chronic cholecystitis in elderly patients. Correlation of the severity of inflammation with the number and size of the stones. In Vivo. 2008;22:269–272.
   PubMed Web of Science ®Google Scholar
• Engle DD, Tiriac H, Rivera KD, et al. The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. Science. 2019;364(6446):1156–1162.
   PubMed Web of Science ®Google Scholar
• Takada A, Ohmori K, Yoneda T, et al. Contribution of carbohydrate antigens sialyl lewis a and sialyl lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res. 1993;53(2):354–361.
   PubMed Web of Science ®Google Scholar
• Takada A, Ohmori K, Takahashi N, et al. Adhesion of human cancer cells to vascular endothelium mediated by a carbohydrate antigen, sialyl lewis A. Biochem Biophys Res Commun. 1991;179(2):713–719.
   PubMed Web of Science ®Google Scholar